Dietary Saccharomyces cerevisiae Cell Wall Extract Supplementation Alleviates Oxidative Stress and Modulates Serum Amino Acids Profiles in Weaned Piglets.
Gang LiuLei YuYordan MartínezWenkai RenHeng-Jia NiNaif Abdullah Al-DhabiVeeramuthu DuraipandiyanYu-Long YinPublished in: Oxidative medicine and cellular longevity (2017)
This research aims to evaluate the effects of dietary supplementation with Saccharomyces cerevisiae cell wall extract (SCCWE) on growth performance, oxidative stress, intestinal morphology, and serum amino acid concentration in weaned piglets. Utilizing a completely randomized design, 40 healthy piglets weaned at 21 d were grouped into 4 experimental treatments with 10 pigs per treatment group. Treatments consisted of a basal diet (T0), a basal diet with a 0.05% SCCWE (T1), a basal diet with a 0.10% SCCWE (T2), and a basal diet with a 0.15% SCCWE (T3). SCCWE supplementation increased the average daily gain and final body weight compared with T0 (P < 0.05). SCCWE in T2 and T3 improved the average daily feed intake and decreased the feed/gain ratio compared with T1 and T2 (P < 0.05). SCCWE decreased serum malondialdehyde (MDA) and increased activities of catalase (CAT), glutathione peroxidase (GPx), and superoxide dismutase (SOD) significantly compared to T0 (P < 0.05). SCCWE increased the concentration of Ile compared to T0 (P < 0.05). Moreover, the concentrations of Leu, Phe, and Arg were higher in T2 and T3 (P < 0.05). These findings indicate beneficial effects of SCCWE supplementation on growth performance, the concentration of some essential amino acids, and alleviation of oxidative stress in weaned piglets.
Keyphrases
- saccharomyces cerevisiae
- oxidative stress
- cell wall
- amino acid
- physical activity
- weight loss
- body weight
- dna damage
- ischemia reperfusion injury
- diabetic rats
- induced apoptosis
- hydrogen peroxide
- double blind
- randomized controlled trial
- breast cancer cells
- cell proliferation
- nitric oxide
- clinical trial
- anti inflammatory
- heat shock protein
- amyotrophic lateral sclerosis
- study protocol
- phase ii
- placebo controlled
- combination therapy